- Home
- OBIO vs AGEN Comparison
OBIO vs AGEN Comparison
Compare OBIO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- AGEN
- Stock Information
- Founded
- OBIO 2017
- AGEN 1994
- Country
- OBIO United States
- AGEN United States
- Employees
- OBIO N/A
- AGEN N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OBIO Health Care
- AGEN Health Care
- Exchange
- OBIO Nasdaq
- AGEN Nasdaq
- Market Cap
- OBIO 205.0M
- AGEN 97.7M
- IPO Year
- OBIO N/A
- AGEN 2000
- Fundamental
- Price
- OBIO $5.83
- AGEN $4.49
- Analyst Decision
- OBIO Strong Buy
- AGEN Buy
- Analyst Count
- OBIO 4
- AGEN 3
- Target Price
- OBIO $15.75
- AGEN $10.00
- AVG Volume (30 Days)
- OBIO 44.2K
- AGEN 339.2K
- Earning Date
- OBIO 11-11-2024
- AGEN 11-05-2024
- Dividend Yield
- OBIO N/A
- AGEN N/A
- EPS Growth
- OBIO N/A
- AGEN N/A
- EPS
- OBIO N/A
- AGEN N/A
- Revenue
- OBIO $2,079,000.00
- AGEN $159,630,000.00
- Revenue This Year
- OBIO $7.68
- AGEN N/A
- Revenue Next Year
- OBIO $110.40
- AGEN $0.04
- P/E Ratio
- OBIO N/A
- AGEN N/A
- Revenue Growth
- OBIO N/A
- AGEN 60.67
- 52 Week Low
- OBIO $4.22
- AGEN $4.18
- 52 Week High
- OBIO $11.69
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- OBIO 60.54
- AGEN 40.14
- Support Level
- OBIO $5.20
- AGEN $4.50
- Resistance Level
- OBIO $5.99
- AGEN $4.78
- Average True Range (ATR)
- OBIO 0.38
- AGEN 0.28
- MACD
- OBIO 0.12
- AGEN 0.02
- Stochastic Oscillator
- OBIO 87.20
- AGEN 42.47
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).